BURLINGTON — Medical-device maker LeMaitre Vascular Inc. said Monday it has acquired Australian-based Xenotis, which makes the Omniflow II biological graft for peripheral bypass and dialysis access, for $7.7 million.
LeMaitre’s products help treat peripheral vascular disease. The company is based at 63 Second Ave.
In a press release, LeMaitre said in its fiscal year ended June 30, Xenotis broke even on sales of $2.3 million, or about $3.4 million if sold through LeMaitre’s sales channel.
Dave Roberts, LeMaitre’s president, said the Omniflow II “has a proven track record, with approximately 20,000 implants since 1990.”
LeMaitre posted 2013 sales of $64.5 million.
